In the fight against myasthenia gravis, there is strength in numbers.

See if you may qualify

The Prevail Study is researching a study medication, gefurulimab (ALXN1720), for adults 18 years of age or older who have been diagnosed with generalized myasthenia gravis (gMG). To learn more and to see if you or your loved one may qualify to participate, talk to your family’s doctor.

Learn more about the Prevail Study.

Reimbursement for travel may be available.